An allosteric modulator of metabotropic glutamate receptors (mGluR₂), (+)-TFMPIP, inhibits restraint stress-induced phasic glutamate release in rat prefrontal cortex.

Journal of Neurochemistry
Erin R HascupGreg A Gerhardt

Abstract

The potential anxiolytic effects of a novel positive allosteric modulator (PAM) of the metabotropic glutamate receptor subgroup 2 (mGluR₂) were investigated using a self-referencing recording technique with enzyme-based microelectrode arrays (MEAs) that reliably measures tonic and phasic changes in extracellular glutamate levels in awake rats. Studies involved glutamate measures in the rat prefrontal cortex during subcutaneous injections of the following: vehicle, a mGluR₂/₃ agonist, LY354740 (10 mg/kg), or a mGluR₂ PAM, 1-Methyl-2-((cis-(R,R)-3-methyl-4-(4-trifluoromethoxy-2-fluoro)phenyl)piperidin-1-yl)methyl)-1H-imidazo[4,5-b]pyridine ((+)-TFMPIP; 1.0 or 17.8 mg/kg). Studies assessed changes in tonic glutamate levels and the glutamatergic responses to a 5-min restraint stress. Subcutaneous injection of (+)-TFMPIP at a dose of 1.0 mg/kg (day 3: -7.1 ± 15.1 net AUC; day 5: -24.8 ± 24.9 net AUC) and 17.8 mg/kg (day 3: -46.5 ± 33.0 net AUC; day 5: 34.6 ± 36.8 net AUC) significantly attenuated the stress-evoked glutamate release compared to vehicle controls (day 3: 134.7 ± 50.6 net AUC; day 5: 286.6 ± 104.5 net AUC), whereas the mGluR₂/₃ agonist LY354740 had no effect. None of the compounds significantly affected resting glutamat...Continue Reading

References

Jan 1, 1992·Pharmacology & Therapeutics·J A Pratt
Jan 12, 1999·Neuroscience and Biobehavioral Reviews·F G GraeffH Zangrossi
Feb 3, 2000·Analytical Chemistry·J J BurmeisterG A Gerhardt
May 23, 2001·Progress in Neurobiology·N C Danbolt
Sep 27, 2002·Journal of Neuroscience Methods·Jason J BurmeisterGreg A Gerhardt
Oct 31, 2002·Human Psychopharmacology·Alan F Schatzberg
Sep 18, 2003·Stress : the International Journal on the Biology of Stress·Darryle D SchoeppWilliam Z Potter
Sep 24, 2004·Bioorganic & Medicinal Chemistry Letters·Essa HuNicholas D P Cosford
Jan 25, 2005·Nature Reviews. Drug Discovery·Chad J SwansonDarryle D Schoepp
Jul 28, 2005·Bioorganic & Medicinal Chemistry Letters·Céline BonnefousTheodore M Kamenecka
Apr 14, 2007·CNS & Neurological Disorders Drug Targets·Jeffrey M WitkinDarryle D Schoepp
May 19, 2007·Brain, Behavior and Evolution·K W S AshwellC R R Watson
Jul 17, 2007·Journal of Neurochemistry·Erin C RutherfordGreg A Gerhardt
Aug 23, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Eduardo DunayevichGary D Tollefson
Nov 21, 2007·The Journal of Pharmacology and Experimental Therapeutics·K N HascupG A Gerhardt
Jun 16, 2009·Progress in Neuro-psychopharmacology & Biological Psychiatry·Zoé Anastasia McElligott, Danny G Winder
Jul 28, 2009·Current Drug Abuse Reviews·M Foster Olive
Sep 1, 2009·The Psychiatric Clinics of North America·Elizabeth I MartinCharles B Nemeroff
Sep 2, 2010·Behavioural Processes·Celio EstanislauSilmara Batistela
Apr 22, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Camilo de la Fuente-SandovalAriel Graff-Guerrero
Apr 29, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Kevin N HascupJan Kehr
May 17, 2011·Pharmacology, Biochemistry, and Behavior·Carlos Riaza Bermudo-SorianoEnrique Baca-Garcia

❮ Previous
Next ❯

Citations

Jun 19, 2014·Molecular Neurobiology·Ti-Fei Yuan, Gonglin Hou
Jan 23, 2020·International Journal of Molecular Sciences·Gokul KrishnaTheresa Currier Thomas
Mar 26, 2019·Journal of Alzheimer's Disease : JAD·Kevin N HascupErin R Hascup

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Polyendocrine Syndromes

This feed focuses on a rare genetic condition called Autoimmune Polyendocrine Syndromes, which are characterized by autoantibodies against multiple endocrine organs. This can lead to Type I Diabetes.